On Thursday, European drugmakers Sanofi and AstraZeneca announced several pipeline cuts in their first quarter of 2024 financial results, including assets to treat Sjögren’s syndrome and cardiovascular disease.

周四，欧洲制药商赛诺菲（Sanofi）和阿斯利康（AstraZeneca）宣布在2024年第一季度的财务报表中削减了几笔资金，包括用于治疗干燥综合征和心血管疾病的资产。

According to Sanofi’s first-quarter results, the development of the CD40L antibody frexalimab in Sjögren’s syndrome was halted due to unfavorable Phase II study data. While Sanofi touted the safety and “pharmacologic activity” of the drug, the candidate did not reach the “necessary efficacy outcomes” to move forward.

根据赛诺菲第一季度的结果，由于不利的II期研究数据，Sjögren综合征中CD40L抗体frexalimab的开发被停止。虽然赛诺菲吹嘘该药物的安全性和“药理活性”，但候选人没有达到“必要的疗效结果”才能取得进展。

However, frexalimab will continue on in Phase III trials in multiple sclerosis (RMS) and secondary-progressive multiple sclerosis (SPMS) as well as Phase II trials in type 1 diabetes and systemic lupus erythematosus..

然而，frexalimab将继续进行多发性硬化症（RMS）和继发性进行性多发性硬化症（SPMS）的III期试验，以及1型糖尿病和系统性红斑狼疮的II期试验。。

In February 2024, frexalimab secured positive mid-stage results in RMS demonstrating a slowing in disease activity. The drug is also one of Sanofi’s “pipeline-in-a-product” assets that the company contends can potentially generate annual sales of €5 billion ($5.3 billion).

2024年2月，frexalimab在RMS中取得了积极的中期结果，表明疾病活动减慢。该药物也是赛诺菲“产品中的管道”资产之一，该公司认为，该资产可能每年产生50亿欧元（53亿美元）的销售额。

Sanofi is also halting a Phase II study of the molecule venglustat to treat the rare genetic disorder GM2 gangliosidosis. The company said there was an “absence of positive trends” for its clinical endpoints in the trial. The molecule aims to slow disease progress by inhibiting the abnormal accumulation of glycosphingolipids.

赛诺菲还停止了对文格司他分子治疗罕见遗传性GM2神经节病的II期研究。该公司表示，该试验的临床终点“没有积极的趋势”。该分子旨在通过抑制鞘糖脂的异常积累来减缓疾病进展。

In 2021, Sanofi stopped a Phase II/III trial of venglustat in kidney disease as it did not reach the futility criteria. .

2021年，赛诺菲停止了文格司他在肾脏疾病中的II/III期试验，因为它没有达到无效标准。

In neurology, Sanofi discontinued a Phase II study of the RIPK1 inhibitor oditrasertib in amyotrophic lateral sclerosis (ALS) as the trial failed to reach the primary endpoint of improvement based on the ALS Functional Rating Scale-Revised. Sanofi said it will share the complete safety and efficacy data at an upcoming medical meeting and continue the Phase II study of oditrasertib in MS patients..

在神经病学方面，赛诺菲停止了对肌萎缩侧索硬化症（ALS）中RIPK1抑制剂奥迪拉西替的II期研究，因为该试验未能根据修订的ALS功能评定量表达到改善的主要终点。赛诺菲表示，它将在即将举行的医学会议上分享完整的安全性和有效性数据，并继续对MS患者进行奥迪司替布的II期研究。。

Sanofi’s pipeline cuts come amid announced layoffs last week as part of the company’s restructuring of its U.S. vaccine operations.

赛诺菲削减生产线之际，上周宣布裁员，这是该公司重组美国疫苗业务的一部分。

Thursday’s Q1 earnings also saw AstraZeneca putting the kibosh on several early-stage medicines, including MEDI6570, designed to block multiple ligands to the LOX-1 receptor. The asset was in a Phase IIb trial, called GOLDILOX, for post-myocardial infarction but was stopped due to a “strategic portfolio prioritization.”.

周四的第一季度财报还显示，阿斯利康（AstraZeneca）推出了几种早期药物，包括MEDI6570，旨在阻断LOX-1受体的多种配体。该资产处于IIb期试验，称为GOLDILOX，用于心肌梗死后，但由于“战略投资组合优先次序”而停止。

Other AstraZeneca assets nixed for portfolio prioritization include the metabolic dysfunction-associated steatohepatitis (MASH) candidate AZD7503. The ligand-conjugated antisense (LICA) drug originally belonged to Ionis Pharmaceuticals and is designed to inhibit the production of hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13). .

其他被禁止进行投资组合优先排序的阿斯利康资产包括代谢功能障碍相关脂肪性肝炎（MASH）候选AZD7503。配体偶联反义（LICA）药物最初属于Ionis Pharmaceuticals，旨在抑制羟基类固醇17β脱氢酶13（HSD17B13）的产生。。

The other  asset to get axed is the oral porcupine inhibitor AZD5055, which was in Phase I trials for Idiopathic pulmonary fibrosis (IPF) and other Interstitial lung diseases (ILDs) with progressive fibrosis. The candidate was picked up from Redx Pharma in 2020 for $17 million and $360 million, respectively, in potential milestone payments..

另一个被解雇的资产是口服豪猪抑制剂AZD5055，它正在进行特发性肺纤维化（IPF）和其他进行性纤维化的间质性肺病（ILD）的I期试验。2020年，该候选人分别以1700万美元和3.6亿美元的潜在里程碑付款从Redx Pharma获得。。

For Sanofi’s Q1 results, the pharma reported over €10.4 billion ($11.2 billion) in sales, driven by its blockbuster drug Dupixent which increased 24.9% compared to the same period. AstraZeneca meanwhile pulled in $12.1 billion in sales for the quarter, a 15% boost from Q1 of 2023, with its oncology products bringing in more than $5.1 billion, a 23% bump from the previous quarter..

对于赛诺菲第一季度的业绩，该制药公司报告销售额超过104亿欧元（112亿美元），受其畅销药Dupixent的推动，与同期相比增长了24.9%。与此同时，阿斯利康本季度销售额为121亿美元，比2023年第一季度增长了15%，其肿瘤产品收入超过51亿美元，比上一季度增长了23%。。